Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020)

Publisher Name :
Date: 10-Dec-2013
No. of pages: 157
Inquire Before Buying

The acute lymphocytic leukemia therapeutics market has growth potential as the incidence rate of the disease is increasing all over the globe. The incidence of acute lymphocytic leukemia is higher in children from 0 to 14 years than in those aged 15 years and above. However, acute lymphocytic leukemia may also occur in adults. The acute lymphocytic leukemia market is segmented into two types—childhood acute lymphocytic leukemia and adult acute lymphocytic leukemia.

The acute lymphocytic leukemia therapeutics market primarily covers regimens and drugs (patented, off-patent, and pipeline). The growing acute lymphocytic leukemia population is an impetus for the growth of the market. This market is expected to grow at a CAGR of 4.0% from 2015 to 2020. In 2012, the overall ALL therapeutics market was dominated by Linker regimen, Hyper-CVAD regimen, and Nucleoside metabolic inhibitors treatments. However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.).

In contrast to the growth of the market, the cost of the therapies is majorly restraining the acute lymphocytic leukemia therapeutics market. In addition, patent expirations of some of the existing drugs in the market are also expected to limit the market growth during 2013 to 2020.

Market players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2008 to November 2013.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms in garnering greater market shares. Firms purchasing the report could use any one or a combination of the below mentioned five strategies (Market Penetration, Product Development/Innovation, Market Development, Market Diversification, and Competitive Assessment) for increasing their market shares.

The report provides insights into the following pointers:


  • Market Penetration: Comprehensive information on products offered by the top players in the acute lymphocytic leukemia therapeutics market. The report analyzes the acute lymphocytic leukemia therapeutics market by existing regimens and drugs, pipeline products, and across all geographies.

  • Product Development/Innovation: Detailed insights into the upcoming trends, research and development activities, and new product launches in the acute lymphocytic leukemia therapeutics market.

  • Market Development: Comprehensive information about the lucrative emerging markets as well as detailed information about the ongoing research and investments in R&D for new products.

  • Market Diversification: Exhaustive information about pipeline product trials, growing geographies, recent developments, and investments in the acute lymphocytic leukemia therapeutics market.

  • Competitive Assessment: In-depth assessment of market shares, growth strategies, products, and manufacturing capabilities of the leading players in the acute lymphocytic leukemia therapeutics market.

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020)

Table Of Contents

1 Introduction
1.1 Objectives of The Study
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size Estimation and Data Triangulation
1.5.2 Market Estimation Model
1.5.3 Key Data Points Taken From Secondary Sources
1.5.4 Assumptions Made For This Report

2 Executive Summary

3 Market Overview
3.1 Defining Leukemia
3.2 Acute Lymphocytic Leukemia
3.2.1 Risk Factors
3.2.2 Stages/Risk Groups of Acute Lymphocytic Leukemia
3.2.2.1 Childhood All
3.2.2.1.1 Standard (LOW) Risk
3.2.2.1.2 High Risk
3.2.2.1.3 Recurrent
3.2.2.2 Adult All
3.2.2.2.1 Untreated Adult All
3.2.2.2.2 Adult All in Remission
3.2.2.2.3 Recurrent Adult All
3.2.3 Diagnosis
3.2.3.1 Biopsy and Bone Marrow Aspiration
3.2.3.2 Complete Blood Count (CBC) and Differential
3.2.3.3 Presence of Philadelphia Chromosome
3.2.3.4 Spinal Tap (Lumbar Puncture) and Cerebrospinal Fluid (CSF) Analysis
3.2.3.5 Immunophenotyping Or Phenotyping By Flow Cytometry
3.2.3.6 Polymerase Chain Reaction (PCR)
3.2.4 Leukemia Prevalence
3.2.5 Incidence & Mortality
3.3 Market Structure
3.3.1 Key Therapies
3.3.1.1 Chemotherapy
3.3.1.2 Stem Cell/Bone Marrow Transplant
3.3.1.3 Radiation Therapy

4 Acute Lymphocytic Leukemia Market Dynamics
4.1 Market Overview
4.2 Market Dynamics
4.2.1 Market Drivers
4.2.1.1 Innovative Therapies to Drive The Market For Acute Lymphocytic Leukemia
4.2.1.2 Oncology Is The Largest Therapeutic Market With High Unmet Needs
4.2.2 Market Restraints
4.2.2.1 Costs Associated With The Treatment
4.2.2.2 Adverse Events of Treatment
4.2.2.3 Low Production Capability of Drugs
4.2.2.4 Genericiazation of The Major Drugs
4.2.3 Market Opportunities
4.2.3.1 Limited Players in The Market
4.2.3.2 Leukemia’s Underserved Patient Populations offer Potential For Market Growth
4.3 Burning Issues
4.4 Winning Imperatives
4.4.1 Market Expansion Through Multiple Therapeutic Approaches

5 Leukemia Product Market
5.1 Market Overview
5.1.1 Hyper-Cvad Regimen
5.1.2 Calgb 8811 Regimen
5.1.3 Linker Regimen
5.1.4 Nucleoside Metabolic Inhibitors (Clolar + Arranon)
5.1.5 Oncaspar

6 Acute Lymphocytic Leukemia Pipeline Molecules (Phase Iii)(Page No. - 73)
6.1 Introduction
6.1.1 Graspa
6.1.2 Marqibo
6.1.3 Inotuzumab Ozogamicin

7 Geographic Analysis
7.1 Introduction
7.2 U.S.
7.3 Canada
7.4 U.K.
7.5 Germany
7.6 France
7.7 Italy
7.8 Spain
7.9 Japan

8 Company Profiles (Overview, Financials, Products Portfolio, Growth Strategy, and Developments)*
8.1 Erytech Pharma
8.2 Genzyme Corporation
8.3 Talon Therapeutics, Inc. (Spectrum Pharmaceuticals, Inc.)
8.4 Sigma-Tau Pharmaceuticals, Inc.
8.5 Pfizer Inc
8.6 Glaxosmithkline Plc

*Details On Financials, Products Portfolio, Growth Strategy, and Developments Might Not  Be Captured in Case of Unlisted Companies.

Competetive Developments (2008 – 2013)
Acquisitions/Collaborations/Partnerships/ Agreements/Joint Ventures, 2008 – 2013
New Product Launches, 2008 – 2013
Expansions/New Facilities/investments, 2008 – 2013 152
Approvals, 2008 – 2013
Developments Related to Clinical Trials, 2008 – 2013 154
Other Developments, 2008 – 2013

List Of Tables

Table 1 Yearly Cost of Drugs in North America & Japan, 2013 ($)
Table 2 Yearly Cost of Drugs in European Countries, 2013 ($)
Table 3 Dosage Pattern of All Drugs
Table 4 Acute Lymphocytic Leukemia Drugs: Patent Status
Table 5 Acute Lymphocytic Leukemia Drugs: Market Revenue, By Type, 2011 – 2020 ($Million)
Table 6 Acute Lymphocytic Leukemia Drugs/Regimens Market Revenue, 2011 – 2020 ($Million)
Table 7 Acute Lymphocytic Leukemia Regimen (Hyper-Cvad) Market Revenue, By Country, 2011 – 2020 ($Million)
Table 8 Acute Lymphocytic Leukemia Regimen (Calgb 8811) Market Revenue, By Country, 2011 – 2020 ($Million)
Table 9 Acute Lymphocyitc Leukemia Drugs (Linker Regimen) Market Revenue, By Country, 2011 – 2020 ($Million)
Table 10 Acute Lymphocytic Leukemia Drug Class (Nucleoside Metabolic Inhibitors) Market Revenue, By Country, 2011 – 2020($Million)
Table 11 Acute Lymphocytic Leukemia Drugs (Oncaspar) Market Revenue, By Country, 2011 – 2020 ($Million)
Table 12 Product Pipeline Molecules: Phase Iii For Acute Lymphocytic Leukemia
Table 13 Acute Lymphocytic Leukemia Drugs – Pipeline (Graspa): Market Revenue, By Country, 2015 – 2020 ($Million)
Table 14 Acute Lymphocytic Leukemia Drugs – Pipeline (Marqibo): Market Revenue, By Country, 2013 – 2020 ($Million)
Table 15 Acute Lymphocytic Leukemia Drugs – Pipeline (Inotuzumab Ozogamicin): Market Revenue, By Country, 2015 – 2020 ($Million)
Table 16 Acute Lymphocytic Leukemia Market in G8 Countries, By Geography, 2011 – 2020 ($Million)
Table 17 U.S.: Acute Lymphocytic Leukemia Epidemiology, 2011 – 2020
Table 18 U.S.: Acute Lymphocytic Leukemia – Existing Regimens/Drugs Market Revenue, 2011 – 2020 ($Million)
Table 19 U.S.: Acute Lymphocytic Leukemia – Pipeline Drugs Market Revenue, 2012 – 2020 ($Million)
Table 20 Canada: Acute Lymphocytic Leukemia Epidemiology, 2011 – 2020
Table 21 Canada: Acute Lymphocytic Leukemia – Existing Regimens/Drugs Market Revenue, 2011 – 2020 ($Million)
Table 22 Canada: Acute Lymphocytic Leukemia – Pipeline Drugs Market Revenue, 2012 – 2020 ($Million)
Table 23 U.K.: Acute Lymphocytic Leukemia Epidemiology, 2011 – 2020
Table 24 U.K.: Acute Lymphocytic Leukemia – Existing Regimens/Drugs Market Revenue, 2011 – 2020 ($Million)
Table 25 U.K.: Acute Lymphocytic Leukemia – Pipeline Drugs Market Revenue, 2012 – 2020 ($Million)
Table 26 Germany: Acute Lymphocytic Leukemia Epidemiology, 2011 – 2020
Table 27 Germany: Acute Lymphocytic Leukemia – Existing Regimens/ Drugs Market Revenue, 2011 – 2020 ($Million)
Table 28 Germany: Acute Lymphocytic Leukemia – Pipeline Drugs Market Revenue, 2012 – 2020 ($Million)
Table 29 France: Acute Lymphocytic Leukemia Epidemiology, 2011 – 2020
Table 30 France: Acute Lymphocytic Leukemia – Existing Regimen/ Drugs Market Revenue, 2011 – 2020 ($Million)
Table 31 France: Acute Lymphocytic Leukemia – Pipeline Drugs Market Revenue, 2012 – 2020 ($Million)
Table 32 Italy: Acute Lymphocytic Leukemia Epidemiology, 2011 – 2020
Table 33 Italy: Acute Lymphocytic Leukemia – Existing Regimens/Drugs Market Revenue, 2011 – 2020 ($Million)
Table 34 Italy: Acute Lymphocytic Leukemia – Pipeline Drugs Market Revenue, 2011 – 2020 ($Million)
Table 35 Italy: Acute Lymphocytic Leukemia – Pipeline Drugs Market Share, 2015 Vs. 2020
Table 36 Spain: Acute Lymphocytic Leukemia Epidemiology, 2011 – 2020
Table 37 Spain: Acute Lymphocytic Leukemia – Existing Regimens/ Drugs Market Revenue, 2011 – 2020 ($Million)
Table 38 Spain: Acute Lymphocytic Leukemia – Pipeline Drugs Market Revenue, 2012 – 2020 ($Million)
Table 39 Japan: Acute Lymphocytic Leukemia Epidemiology, 2011 – 2020
Table 40 Japan: Acute Lymphocytic Leukemia – Existing Regimens/ Drugs Market Revenue, 2011 – 2020 ($Million)
Table 41 Japan: Acute Lymphocytic Leukemia – Pipeline Drugs Market Revenue, 2011 – 2020 ($Million)
Table 42 Erytech Pharma: Product Pipeline
Table 43 Erytech: Total Operating Revenue and R&D Expenditure, 2010 – 2012 ($Million)
Table 44 Genzyme Corporation: Product Portfolio
Table 45 Genzyme Corporation: Total Revenue and R&D Expenditure, 2008 – 2010 ($Million)
Table 46 Talon Therapeutics, inc.: Pipeline Product Portfolio
Table 47 Talon Therapeutics, inc.: Total R&D Expenditure, 2008 – 2012 ($Million)
Table 48 Sigma – Tau Group: Total Revenue, 2008 – 2012 ($Million)
Table 49 Pfizer, inc.: Total Revenue and R&D Expenditure, 2008 – 2012 ($Million)
Table 50 Galxosmithkline PLC: Total Revenue & R&D Expenses, 2008 – 2012 ($Million)

List Of Figures

Figure 1 Acute Lymphocytic Leukemia Market in G8 Countries, By Existing Regimens/Drugs ($Million)
Figure 2 Acute Lymphocytic Leukemia Market in G8 Countries, By Product Pipeline ($Million)
Figure 3 Status of Acute Lymphocytic Leukemia Product Pipeline
Figure 4 Acute Lymphocytic Leukemia Market, By Country
Figure 5 Most Common Types of Leukemia
Figure 6 Total Leukemia Population, By Country, 2008 – 2020
Figure 7 Acute Lymphocytic Leukemia: Age At Diagnosis
Figure 8 Stages and Phases of Acute Lymphocytic Leukemia
Figure 9 Acute Lymphocytic Leukemia: Population, By Country, 2008 – 2020
Figure 10 Market Revenue, By Top 10 Therapeutic Class ($Billion)
Figure 11 Erytech and Talon: Product Pipeline
Figure 12 Acute Lymphocytic Leukemia Existing Regimens/Drugs Market Share, By Types, 2013 Vs 2015 Vs 2020
Figure 13 Acute Lymphocytic Leukemia Pipeline Regimens/Drugs Market Share, By Types, 2015 Vs 2020
Figure 14 U.S.: Acute Lymphocytic Leukemia – Existing Regimens/Drugs Market Share, 2013 Vs. 2015 Vs. 2020 ($Million)
Figure 15 U.S: Acute Lymphocytic Leukemia – Pipeline Drugs Market Share, 2015 Vs. 2020
Figure 16 Canada: Acute Lymphocytic Leukemia – Existing Regimens/ Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 17 Canada: Acute Lymphocytic Leukemia – Pipeline Drugs Market Share, 2015 Vs. 2020
Figure 18 U.K.: Acute Lymphocytic Leukemia – Existing Regimens/ Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 19 U.K.: Acute Lymphocytic Leukemia – Pipeline Drugs Market Share, 2015 Vs. 2020
Figure 20 Germany: Acute Lymphocytic Leukemia – Existing Regimens/Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 21 Germany: Acute Lymphocytic Leukemia – Pipeline Drugs Market Share, 2015 Vs. 2020
Figure 22 France: Acute Lymphocytic Leukemia – Existing Regimens/Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 23 France: Acute Lymphocytic Leukemia – Pipeline Drugs Market Share, 2015 Vs. 2020
Figure 24 Italy: Acute Lymphocytic Leukemia – Existing Regimens/ Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 25 Spain: Acute Lymphocytic Leukemia – Existing Regimens/ Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 26 Spain: Acute Lymphocytic Leukemia – Pipeline Drugs Market Share, 2015 Vs. 2020
Figure 27 Japan: Acute Lymphocytic Leukemia – Existing Regimens/Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 28 Japan: Acute Lymphocytic Leukemia – Pipeline Drugs Market Share, 2015 Vs. 2020

  • Global Circulating Tumor Cells Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 08-Dec-2016        Price: US 3480 Onwards        Pages: 110
    This report mainly covers Circulating Tumor Cells products, by types (CTC enrichment, CTC detection and CTC analysis), by applications (Prostate Cancer, Breast Cancer, Colorectal Cancer Diagnosis and Treatment and Others).Scope of the Report:This report focuses on the Circulating Tumor Cells in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type ......
  • Metastatic Breast Cancer - Pipeline Review, H2 2016
    Published: 07-Dec-2016        Price: US 2500 Onwards        Pages: 1096
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Breast Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Breast Cancer (Oncology) pipeline landscape.Metastatic breast cancer (also called Stage IV or Advanced) is a stage of breast cancer in which cancer cells break away from the tumor in the breast, spread to other parts of the body and keep growing. Symptoms of metastatic breast cancer includes severe, progressive pain, an......
  • United States Testicular Implant Market Report 2016
    Published: 05-Dec-2016        Price: US 3800 Onwards        Pages: 104
    Notes: Sales, means the sales volume of Testicular Implant Revenue, means the sales value of Testicular Implant This report studies sales (consumption) of Testicular Implant in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - AART - Allied Biomedical - Coloplast - Nagor - Polytech Health & Aesthetics - Promedon - Sebbin - UROMED ......
  • United States Non-small Cell Lung Cancer Therapeutics Market Report 2016
    Published: 01-Dec-2016        Price: US 3800 Onwards        Pages: 117
    Notes: Sales, means the sales volume of Non-small Cell Lung Cancer Therapeutics Revenue, means the sales value of Non-small Cell Lung Cancer Therapeutics This report studies sales (consumption) of Non-small Cell Lung Cancer Therapeutics in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Bristol-Myers Squibb - GlaxoSmithKline - Menarini - Sanofi - ZIOPHARM Onco......
  • Vulvar Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 76
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer - Pipeline Review, H2 2016, provides an overview of the Vulvar Cancer (Oncology) pipeline landscape.Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into c......
  • Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 477
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides an overview of the Refractory Acute Myeloid Leukemia (Oncology) pipeline landscape.The acute myeloid leukemia cells which resist treatment are referred to as refractory acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfo......
  • Small-Cell Lung Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 588
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2016, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spr......
  • Gallbladder Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 74
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2016, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts......
  • Vaginal Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Pipeline Review, H2 2016, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal intraepithelial neoplasia. Treatment include......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs